Reata Pharmaceuticals, Inc.
NASDAQ: RETA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- J. Warren Huff
- Employees
- 321
- Headquarters
- Plano, United States
- IPO year
- 2016
- Market cap
- $6.6B
- Website
- https://www.reatapharma.com
Loading RETA…
Loading profile data…Frequently asked questions about RETA
What does Reata Pharmaceuticals, Inc. (RETA) do?
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for individuals afflicted with severe or life-threatening illnesses. A key focus is bardoxolone methyl (often referred to as bardoxolone), which is currently undergoing Phase 3 clinical trials f...
Where does RETA trade?
Reata Pharmaceuticals, Inc. (RETA) trades on the NASDAQ Global Market.
What sector is RETA in?
Reata Pharmaceuticals, Inc. (RETA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Reata Pharmaceuticals, Inc.?
J. Warren Huff is the chief executive officer of Reata Pharmaceuticals, Inc. (RETA).
Where is Reata Pharmaceuticals, Inc. headquartered?
Reata Pharmaceuticals, Inc. is headquartered in United States.
Does RETA pay a dividend?
Reata Pharmaceuticals, Inc. (RETA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RETA go public?
Reata Pharmaceuticals, Inc. (RETA) completed its initial public offering in 2016.